US 12,264,159 B2
Functionalized heterocycles as antiviral agents
Joseph D. Panarese, Newton, MA (US); Dexter Davis, Watertown, MA (US); Samuel Bartlett, Brighton, MA (US); Katherine Chong, Belmont, MA (US); Nathaniel Thomas Kenton, Watertown, MA (US); and Yat Sun Or, Waltham, MA (US)
Assigned to Enanta Pharmaceuticals, Inc., Watertown, MA (US)
Filed by Enanta Pharmaceuticals, Inc., Watertown, MA (US)
Filed on Dec. 18, 2023, as Appl. No. 18/543,151.
Application 18/543,151 is a continuation of application No. 17/517,740, filed on Nov. 3, 2021, granted, now 11,891,393.
Application 17/517,740 is a continuation of application No. 16/689,448, filed on Nov. 20, 2019, granted, now 11,198,693, issued on Dec. 14, 2021.
Claims priority of provisional application 62/770,428, filed on Nov. 21, 2018.
Claims priority of provisional application 62/884,486, filed on Aug. 8, 2019.
Prior Publication US 2024/0262828 A1, Aug. 8, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4985 (2006.01); C07D 471/14 (2006.01); A61K 45/06 (2006.01)
CPC C07D 471/14 (2013.01) [A61K 45/06 (2013.01)] 19 Claims
 
1. A pharmaceutical composition comprising a compound selected from the group consisting of

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or ester thereof,
and a pharmaceutically acceptable carrier or excipient.